6 news items
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
NRBO
22 May 24
and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NRBO
9 May 24
and consulting and (ii) $0.4 million in higher employee compensation and benefits
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NRBO
17 Apr 24
candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NRBO
1 Apr 24
to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
NRBO
28 Mar 24
million in higher employee compensation and benefits
zusepw
NRBO
13 Mar 24
candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating
- Prev
- 1
- Next